Search results
Kansas Attorney General Kris Kobach sues Pfizer over marketing of COVID-19 vaccine
The Kansas City Star· 1 day agoKansas Attorney General Kris Kobach is suing the pharmaceutical company Pfizer, alleging it deceptively marketed its COVID-19 vaccine. The lawsuit, filed in state court in ...
A new Alzheimer's drug, combined COVID and flu vaccine update, and salmonella concerns. 3 health...
Yahoo Life Style via AOL· 4 days agoWhat it means for you: If you skip your flu shot each year, there’s good news: Moderna found that...
Moderna’s Covid-19 vaccine meets primary efficacy endpoint in Phase III trial
Clinical Trials Arena via Yahoo Finance· 5 days agoIn terms of safety, mRNA-1283 was found to have a profile similar to that of Spikevax, with the most...
CyanVac secures funding for Phase IIb intranasal Covid-19 vaccine trial
Clinical Trials Arena via Yahoo Finance· 5 days ago“PIV5 is a novel intranasal vaccine vector that has been shown to replicate safely in humans in...
Results are looking promising for a combined COVID and flu vaccine. Here’s how it could benefit...
The Conversation· 5 days agoEarlier this week, Moderna announced positive results for its phase 3 clinical trial of a combined vaccine against COVID and influenza. Combination vaccines
Moderna's mRNA-1283 vaccine shows promise in Phase 3 trial By Investing.com
Investing.com· 6 days agoModerna , Inc. (NASDAQ:MRNA) has announced successful results from the Phase 3 trial of its...
Kansas accuses Pfizer of misleading public about COVID vaccine in lawsuit
Reuters· 1 day ago, opens new tab filed in the District Court of Thomas County, the state said the New York-based drugmaker's alleged false statements violated the Kansas Consumer Protection Act. "Pfizer made ...
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation...
The Kansas City Star· 6 days agomRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax® in participants 12 years of age and older
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation...
Morningstar· 6 days agoCAMBRIDGE, MA / ACCESSWIRE / June 13, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that its Phase 3 trial of mRNA-1283, an investigational next-generation COVID-19 vaccine< ...
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation...
Digital Journal· 6 days agomRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax ...